Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4.

ABSTRACT:

Importance

Age-related cataract is a leading cause of visual impairment in the United States. The prevalence of age-related cataract is increasing, with an estimated 30.1 million Americans likely to be affected by 2020.

Objective

To determine whether daily oral supplementation with lutein/zeaxanthin affects the risk for cataract surgery.

Design, setting, and patients

The Age-Related Eye Disease Study 2 (AREDS2), a multicenter, double-masked clinical trial, enrolled 4203 participants, aged 50 to 85 years, at risk for progression to advanced age-related macular degeneration.

Interventions

Participants were randomly assigned to daily placebo; lutein/zeaxanthin, 10mg/2mg; omega-3 long-chain polyunsaturated fatty acids, 1 g; or a combination to evaluate the effects

SUBMITTER: Age-Related Eye Disease Study 2 (AREDS2) Research Group 

PROVIDER: S-EPMC6774801 | biostudies-literature | 2013 Jul

REPOSITORIES: biostudies-literature